Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | DDX3X | O00571 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.51 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.49 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.49 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.49 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.49 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.49 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | PDK1 | Q15118 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3209453 | 0.88 | ALDH1A1 (0.66) | ALDH1A1DDX3XSMN1; SMN2PTGS1NPSR1 | |
| SCHEMBL19675849 | 0.86 | ALDH1A1 (0.64) | ALDH1A1DDX3XSMN1; SMN2PTGS1NPSR1 | |
| SCHEMBL1415228 | 0.82 | ALDH1A1 (0.58) | ALDH1A1DDX3XSMN1; SMN2PTGS1NPSR1 | |
| SCHEMBL16444667 | 0.81 | ALDH1A1 (0.57) | ALDH1A1DDX3XSMN1; SMN2PTGS1NPSR1 | |
| SCHEMBL6660855 | 0.81 | HSD17B10 (0.62) | ALDH1A1SMN1; SMN2NPSR1GAA | |
| SCHEMBL2723870 | 0.81 | L3MBTL1 (0.65) | ALDH1A1DDX3XSMN1; SMN2PTGS1MAPT | |
| SCHEMBL11423971 | 0.81 | DDX3X (0.65) | ALDH1A1DDX3XSMN1; SMN2PTGS1NPSR1 | |
| SCHEMBL374432 | 0.78 | ALDH1A1 (1.00) | ALDH1A1DDX3XSMN1; SMN2PTGS1MAPT | |
| SCHEMBL29557251 | 0.78 | ALDH1A1 (1.00) | ALDH1A1DDX3XSMN1; SMN2PTGS1MAPT | |
| SCHEMBL20124849 | 0.78 | MAPT (0.57) | ALDH1A1PTGS1MAPTL3MBTL1PDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | SCHULZE KLAUSE | 2010-02-25 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| US-7511059-B2 | Thiazolidinones, their production and use as pharmaceutical agents | SCHERING AG (DE) | 2009-03-31 | — | — | US | disclosed |
| CN-101155791-A | Thiazolidinones for use as inhibitors of polo-like kinase (plk) | BAYER SCHERING PHARMA AG (DE) | 2008-04-02 | — | — | CN | disclosed |
| CN-101146782-A | Meta-substituted thiazolidinone compounds, process for their preparation and their use as medicaments | BAYER SCHERING PHARMA AG (DE) | 2008-03-19 | — | — | CN | disclosed |
| EP-1844027-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-10-17 | — | — | EP | disclosed |
| EP-1824834-A1 | META-SUBSTITUTED THIAZOLIDINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-01-18 | — | — | US | disclosed |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-05 | — | — | US | disclosed |
| WO-2006082107-A1 | THIAZOLIDINONES FOR USE AS INHIBITORS OF POLO-LIKE KINASE (PLK) | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006063806-A1 | META-SUBSTITUTED THIAZOLIDINONES, THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-06-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048891-A1 | METASUBSTITUTED THIAZOLIDINONES, THEIR MANUFACTURE AND USE AS A DRUG | PLK2, PDXK, PLK4 | ALDH1A1 1600/4885DDX3X 3284/4885SMN1; SMN2 2774/4885 |
| US-20060223833-A1 | Thiazolidinones, their production and use as pharmaceutical agents | PLK2, PLK4, PLK3 | ALDH1A1 963/4885DDX3X 2946/4885SMN1; SMN2 4365/4885 |
| US-20070015759-A1 | Metasubstituted thiazolidinones, their manufacture and use as a drug | PLK4, PDXK, PLK2 | ALDH1A1 997/4885DDX3X 3444/4885SMN1; SMN2 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.